NIH selects Viamet's novel antifungal compound for inclusion in the TRND program
Links shared publicly online about this topic.
- 112total visits
NIH selects Viamet's novel antifungal compound for inclusion in the TRND program
Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.
View full resource at news-medical.net
Tags: Meningitis, Disease and Condition, Pharma, National Institutes of Health, News, disease
Most Recently Shared on July 29, 2011 at 2:17 pm By:
Oncology News: NIH selects Viamet's novel antifungal compound for inclusion in the TRND program: Viamet Pharmace... http://bit.ly/qXWlPw
Also Shared By:
Advertisement
News-Medical.Net
@Meningitis_News
Meningitis News: NIH selects Viamet's novel antifungal compound for inclusion in the TRND program: Viamet Pharma... http://bit.ly/qXWlPw
1 year ago...